Press Releases - Emmaus Medical, Inc.

Emmaus Life Sciences Provides Operational UpdatesJune 02, 2020

Emmaus Life Sciences, Inc., provided today operational updates in advance of the filing of its 10-K for the year ended December 31, 2019 and its 10-Q for the first quarter of 2020.

APCER Report Confirms Endari ® SafetyApril 27, 2020

Emmaus announced today that APCER Life Sciences (APCER) has confirmed the safety profile of Endari®, Emmaus’ prescription grade L-glutamine oral powder for the treatment of sickle cell disease.

Emmaus Life Sciences Announces SFDA (Saudi Food & Drug Authority) Accepts Endari® Priority Review RequestApril 16, 2020

Emmaus announced today that the SFDA (Saudi Food & Drug Authority) has accepted its request for priority review of Endari®.

Emmaus Life Sciences Provides Update in Response to the Coronavirus (COVID-19) PandemicMarch 24, 2020

Within the overall SCD community, Emmaus is working in coordination with the Sickle Cell Disease Association of America and other organizations to educate and communicate with the SCD community during this challenging time.

Emmaus Life Sciences Announces Equity Purchase Agreement for up to $25 Million with Lincoln Park CapitalMarch 03, 2020

Emmaus Life Sciences, Inc., announced today the execution of a purchase agreement for up to $25 million of common stock with Lincoln Park Capital Fund, LLC (“LPC”), a long-only Chicago-based institutional investor.